Pseudomyxoma peritonei: current chemotherapy and the need for mucin-directed strategies

Bibliography

• Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 2008;34(2):196-201
   PubMed Web of Science ®Google Scholar
• Misdraji J. Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med 2010;134(6):864-70
   PubMed Web of Science ®Google Scholar
• Werth R. Klinische und anatomische untersuchungen zur lehre von den bauchgeschwülsten und der laparatomie. Arch Gynakol 1884;24(1):100-18
   Google Scholar
• Fraenkel E. Ueber das sogennante pseudomyxoma perotonei. Munch med wochenschr 1901;48:965-71
   Google Scholar
• Ronnett BM, Shmookler BM, Diener-West M, et al. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol 1997;16(1):1-9
   PubMed Web of Science ®Google Scholar
• Szych C, Staebler A, Connolly DC, et al. Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol 1999;154(6):1849-55
   PubMed Web of Science ®Google Scholar
• O’Connell JT, Tomlinson JS, Roberts AA, et al. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol 2002;161(2):551-64
   PubMed Web of Science ®Google Scholar
• Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol 1995;19(12):1390-408
   PubMed Web of Science ®Google Scholar
• Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001;92(1):85-91
   PubMed Web of Science ®Google Scholar
• Bradley RF, Stewart JH, Russell GB, et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006;30(5):551-9
   PubMed Web of Science ®Google Scholar
• Shetty S, Natarajan B, Thomas P, et al. Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am Surg 2013;79(11):1171-6
   PubMed Web of Science ®Google Scholar
• Buell-Gutbrod R, Gwin K. Pathologic diagnosis, origin, and natural history of pseudomyxoma peritonei. Am Soc Clin Oncol Educ Book 2013;33:221-5
   Google Scholar
• Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 1994;219(2):109-11
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. The natural history, gross pathology, and histopathology of appendiceal epithelial neoplasms. Eur J Surg Oncol 2006;32(6):644-7
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Pseudomyxoma peritonei. Cancer Treat Res 1996;81:105-19
   PubMedGoogle Scholar
• Yan TD, Stuart OA, Yoo D, Sugarbaker PH. Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. J Transl Med 2006;4:17
   PubMed Web of Science ®Google Scholar
• Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4(1):45-60
   PubMed Web of Science ®Google Scholar
• O’Connell JT, Hacker CM, Barsky SH. MUC2 is a molecular marker for pseudomyxoma peritonei. Mod Pathol 2002;15(9):958-72
   PubMed Web of Science ®Google Scholar
• Mall AS, Chirwa N, Govender D, et al. MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study. Pathol Int 2007;57(8):537-47
   PubMed Web of Science ®Google Scholar
• Mall AS, Lotz Z, Tyler M, et al. Immunohistochemical and biochemical characterization of mucin in pseudomyxoma peritonei: a case study. Case Rep Gastroenterol 2011;5(1):5-16
   PubMedGoogle Scholar
• Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30(20):2449-56
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonei syndrome. Adv Surg 1996;30:233-80
   PubMedGoogle Scholar
• Esquivel J, Sugarbaker PH. Clinical presentation of the Pseudomyxoma peritonei syndrome. Br J Surg 2000;87(10):1414-18
   PubMed Web of Science ®Google Scholar
• Smeenk RM, Bruin SC, van Velthuysen ML, Verwaal VJ. Pseudomyxoma peritonei. Curr Probl Surg 2008;45(8):527-75
   PubMed Web of Science ®Google Scholar
• Esquivel J, Sugarbaker PH. Pseudomyxoma peritonei in a hernia sac: analysis of 20 patients in whom mucoid fluid was found during a hernia repair. Eur J Surg Oncol 2001;27(1):54-8
   PubMedGoogle Scholar
• Skaane P, Isachsen MM, Hoiseth A. Computed tomography of mucin-producing adenocarcinoma of the appendix presenting as a bladder tumor. J Comput Assist Tomogr 1985;9(3):566-7
   PubMed Web of Science ®Google Scholar
• Gandhi VV, Nagral S. Pseudomyxoma peritonea: uncommon presentation. Indian J Surg 2012;74(2):172-3
   PubMed Web of Science ®Google Scholar
• Snyder TE, Vandivort MR. Mucinous cystadenocarcinoma of the appendix with pseudomyxoma peritonei presenting as total uterine prolapse. A case report. J Reprod Med 1992;37(1):103-6
   PubMed Web of Science ®Google Scholar
• Newman CM, Moran BJ. Pseudomyxoma peritonei presenting as recurrent rectal cancer: a preventable condition? Tech Coloproctol 2011;15(1):89-90
   PubMed Web of Science ®Google Scholar
• Koyama S, Tomimatsu T, Sawada K, et al. Pseudomyxoma peritonei originating from colorectal cancer during pregnancy. J Obstet Gynaecol Res 2011;37(3):254-8
   PubMed Web of Science ®Google Scholar
• Abdu B, Hobgood D, Stallings S, Depasquale S. Incidental finding of pseudomyxoma peritonei at primary cesarean section. Am J Perinatol 2009;26(9):633-5
   PubMed Web of Science ®Google Scholar
• Cakmak A, Karakayali F, Bayar S, et al. Pseudomyxoma retroperitonei presenting with a skin fistula. Turk J Gastroenterol 2009;20(1):79-80
   PubMed Web of Science ®Google Scholar
• Srinivasaiah N, Retnasingam G, Kasarneni R, Slater B. Pseudomyxoma peritonei: a rare presentation as an umbilical nodule. Ir J Med Sci 2009;178(2):219-21
   PubMed Web of Science ®Google Scholar
• Kreel L, Bydder GM. Computed tomography of fluid collections within the abdomen. J Comput Tomogr 1980;4(2):105-15
   PubMedGoogle Scholar
• Sulkin TV, O’Neill H, Amin AI, Moran B. CT in pseudomyxoma peritonei: a review of 17 cases. Clin Radiol 2002;57(7):608-13
   PubMed Web of Science ®Google Scholar
• Smeenk RM, Verwaal VJ, Zoetmulder FA. Pseudomyxoma peritonei. Cancer Treat Rev 2007;33(2):138-45
   PubMed Web of Science ®Google Scholar
• Buy JN, Malbec L, Ghossain MA, et al. Magnetic resonance imaging of pseudomyxoma peritonei. Eur J Radiol 1989;9(2):115-18
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Masumoto T, Suzuki K, et al. Pseudomyxoma retroperitonei. Eur Radiol 1999;9(3):457-9
   PubMed Web of Science ®Google Scholar
• Fairise A, Barbary C, Derelle A, et al. [Mucocele of the appendix and pseudomyxoma peritonei]. J Radiol 2008;89(6):751-62
   PubMed Web of Science ®Google Scholar
• Yang QM, Bando E, Kawamura T, et al. The diagnostic value of PET-CT for peritoneal dissemination of abdominal malignancies. Gan To Kagaku Ryoho 2006;33(12):1817-21
   PubMedGoogle Scholar
• Passot G, Glehen O, Pellet O, et al. Pseudomyxoma peritonei: role of 18F-FDG PET in preoperative evaluation of pathological grade and potential for complete cytoreduction. Eur J Surg Oncol 2010;36(3):315-23
   PubMed Web of Science ®Google Scholar
• Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 2005;12(10):765-77
   PubMed Web of Science ®Google Scholar
• Rohani P, Scotti SD, Shen P, et al. Use of FDG-PET imaging for patients with disseminated cancer of the appendix. Am Surg 2010;76(12):1338-44
   PubMed Web of Science ®Google Scholar
• Carmignani CP, Hampton R, Sugarbaker CE, et al. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 2004;87(4):162-6
   PubMed Web of Science ®Google Scholar
• Alexander-Sefre F, Chandrakumaran K, Banerjee S, et al. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence. Colorectal Dis 2005;7(4):382-6
   PubMed Web of Science ®Google Scholar
• van Ruth S, Hart AA, Bonfrer JM, et al. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002;9(10):961-7
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Martinetti A, et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2007;14(8):2300-8
   PubMed Web of Science ®Google Scholar
• Chua TC, Chong CH, Liauw W, et al. Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy. Ann Surg 2012;256(2):342-9
   PubMed Web of Science ®Google Scholar
• Koh JL, Liauw W, Chua T, Morris DL. Carbohydrate antigen 19-9 (CA 19-9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Gastrointest Oncol 2013;4(2):173-81
   Google Scholar
• Kusamura S, Hutanu I, Baratti D, Deraco M. Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei. J Surg Oncol 2013;108(1):1-8
   PubMed Web of Science ®Google Scholar
• Taflampas P, Dayal S, Chandrakumaran K, et al. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: analysis of 519 patients. Eur J Surg Oncol 2014;40(5):515-20
   PubMed Web of Science ®Google Scholar
• Bibi R, Pranesh N, Saunders MP, et al. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. Br J Cancer 2006;95(9):1258-64
   PubMed Web of Science ®Google Scholar
• Semino-Mora C, Liu H, McAvoy T, et al. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol 2008;15(5):1414-23
   PubMed Web of Science ®Google Scholar
• Flatmark K, Davidson B, Kristian A, et al. Exploring the peritoneal surface malignancy phenotype – a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models. Hum Pathol 2010;41(8):1109-19
   PubMed Web of Science ®Google Scholar
• Guo AT, Song X, Wei LX, Zhao P. Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry. World J Gastroenterol 2011;17(30):3531-7
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg 2009;249(2):243-9
   PubMed Web of Science ®Google Scholar
• Clement PB, Granai CO, Young RH, Scully RE. Endometriosis with myxoid change. A case simulating pseudomyxoma peritonei. Am J Surg Pathol 1994;18(8):849-53
   PubMed Web of Science ®Google Scholar
• Sugi Subramaniam RV, Karthikeyan VS, Sistla SC, et al. Melioidosis presenting as pseudomyxoma peritonei: yet another pretense of the great mimicker: an unreported entity. Surg Infect (Larchmt) 2013;14(4):415-17
   PubMed Web of Science ®Google Scholar
• Mirich DR, Gray RR, Grosman H. Abdominal plexiform neurofibromatosis simulating pseudomyxoma peritonei on computed tomography. J Comput Assist Tomogr 1989;13(4):709-11
   PubMed Web of Science ®Google Scholar
• Jarvinen P, Jarvinen HJ, Lepisto A. Survival of patients with pseudomyxoma peritonei treated by serial debulking. Colorectal Dis 2010;12(9):868-72
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Kern K, Lack E. Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment. Dis Colon Rectum 1987;30(10):772-9
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001;27(3):239-43
   PubMedGoogle Scholar
• Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7(1):69-76
   PubMed Web of Science ®Google Scholar
• van Ruth S, Verwaal VJ, Zoetmulder FA. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 2003;12(3):771-80
   PubMedGoogle Scholar
• Farquharson AL, Pranesh N, Witham G, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 2008;99(4):591-6
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Maggi C, Fanetti G, et al. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist 2014;19(8):845-50
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Bijelic L. Adjuvant bidirectional chemotherapy using an intraperitoneal port. Gastroenterol Res Pract 2012;2012:752643
   PubMedGoogle Scholar
• Li JD, Feng W, Gallup M, et al. Activation of NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells. Proc Natl Acad Sci USA 1998;95(10):5718-23
   PubMed Web of Science ®Google Scholar
• Perrais M, Pigny P, Copin MC, et al. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem 2002;277(35):32258-67
   PubMed Web of Science ®Google Scholar
• Choudry HA, O’Malley ME, Guo ZS, et al. Mucin as a therapeutic target in pseudomyxoma peritonei. J Surg Oncol 2012;106(7):911-17
   PubMed Web of Science ®Google Scholar
• Lohani K, Shetty S, Sharma P, et al. Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment. Ann Surg Oncol 2014;21(5):1441-7
   PubMed Web of Science ®Google Scholar
• Enss ML, Cornberg M, Wagner S, et al. Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180. Inflamm Res 2000;49(4):162-9
   PubMed Web of Science ®Google Scholar
• Kim YD, Kwon EJ, Kwon TK, et al. Regulation of IL-1beta-mediated MUC2 gene in NCI-H292 human airway epithelial cells. Biochem Biophys Res Commun 2000;274(1):112-16
   PubMed Web of Science ®Google Scholar
• Iwashita J, Sato Y, Sugaya H, et al. mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogen-activated protein kinase pathway in human colon cancer cells. Immunol Cell Biol 2003;81(4):275-82
   PubMed Web of Science ®Google Scholar
• Kai H, Yoshitake K, Hisatsune A, et al. Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells. Am J Physiol 1996;271(3 Pt 1):L484-8
   PubMed Web of Science ®Google Scholar
• Schoneveld OJ, Gaemers IC, Lamers WH. Mechanisms of glucocorticoid signalling. Biochim Biophys Acta 2004;1680(2):114-28
   PubMed Web of Science ®Google Scholar
• Choudry HA, Mavanur A, O’Malley ME, et al. Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei. Ann Surg Oncol 2012;19(5):1402-9
   PubMed Web of Science ®Google Scholar
• Okudaira K, Kakar S, Cun L, et al. MUC2 gene promoter methylation in mucinous and non-mucinous colorectal cancer tissues. Int J Oncol 2010;36(4):765-75
   PubMed Web of Science ®Google Scholar
• Aslam F, Palumbo L, Augenlicht LH, Velcich A. The Sp family of transcription factors in the regulation of the human and mouse MUC2 gene promoters. Cancer Res 2001;61(2):570-6
   PubMed Web of Science ®Google Scholar
• Chua TC, Liauw W, Morris DL. The St George Hospital Peritoneal Surface Malignancy Program--where are we now? ANZ J Surg 2009;79(6):416-18
   PubMed Web of Science ®Google Scholar
• Chua TC, Akther J, Yao P, Morris DL. In vivo model of pseudomyxoma peritonei for novel candidate drug discovery. Anticancer Res 2009;29(10):4051-5
   PubMed Web of Science ®Google Scholar
• Akhter J, Yao P, Johnson LA, et al. A new peritoneal carcinomatosis model in cyclosporine immunosuppressed rats. Anticancer Res 2008;28;1A:105-8
   Google Scholar
• Pillai K, Akhter J, Chua TC, Morris DL. Mucolysis by ascorbic acid and hydrogen peroxide on compact mucin secreted in pseudomyxoma peritonei. J Surg Res 2012;174(2):e69-73
   PubMed Web of Science ®Google Scholar
• Pillai K, Akhter J, Chua TC, Morris DL. Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei. Invest New Drugs 2012;30(5):2080-6
   PubMed Web of Science ®Google Scholar
• Amini A, Ehteda A, Masoumi Moghaddam S, et al. Cytotoxic effects of bromelain in human gastrointestinal carcinoma cell lines (MKN45, KATO-III, HT29-5F12, and HT29-5M21). Onco Targets Ther 2013;6:403-9
   PubMed Web of Science ®Google Scholar
• Pillai K, Akhter J, Chua TC, Morris DL. Anticancer property of bromelain with therapeutic potential in malignant peritoneal mesothelioma. Cancer Invest 2013;31(4):241-50
   PubMed Web of Science ®Google Scholar
• Pillai K, Ehteda A, Akhter J, et al. Anticancer effect of bromelain with and without cisplatin or 5-FU on malignant peritoneal mesothelioma cells. Anticancer Drugs 2014;25(2):150-60
   PubMed Web of Science ®Google Scholar
• Amini A, Masoumi-Moghaddam S, Ehteda A, Morris DL. Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: significance of combination therapy. J Exp Clin Cancer Res 2014;33:92
   PubMed Web of Science ®Google Scholar
• Pillai K, Akhter J, Chua TC, Morris DL. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei. Int J Cancer 2014;134(2):478-86
   PubMed Web of Science ®Google Scholar
• Akhter J, Pillai K, Chua TC, et al. Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters. Am J Cancer Res 2014;4(5):495-507
   Web of Science ®Google Scholar
• Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980;40(2):256-60
   PubMed Web of Science ®Google Scholar
• Mohamed F, Gething S, Haiba M, et al. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process. J Surg Oncol 2004;86(1):10-15
   PubMed Web of Science ®Google Scholar
• Nonaka D, Kusamura S, Baratti D, et al. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Histopathology 2006;49(4):381-7
   PubMed Web of Science ®Google Scholar
• Ferreira CR, Carvalho JP, Soares FA, et al. Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors. Int J Gynecol Cancer 2008;18(1):59-65
   PubMed Web of Science ®Google Scholar
• Chang MS, Byeon SJ, Yoon SO, et al. Leptin, MUC2 and mTOR in appendiceal mucinous neoplasms. Pathobiology 2012;79(1):45-53
   PubMed Web of Science ®Google Scholar
• Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 2010;36(5):456-62
   PubMed Web of Science ®Google Scholar
• Arjona-Sanchez A, Munoz-Casares FC, Rufian-Pena S, et al. Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre. Clin Transl Oncol 2011;13(4):261-7
   PubMed Web of Science ®Google Scholar
• Austin F, Mavanur A, Sathaiah M, et al. Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol 2012;19(5):1386-93
   PubMed Web of Science ®Google Scholar
• Arjona-Sanchez A, Munoz-Casares FC, Casado-Adam A, et al. Outcome of patients with aggressive pseudomyxoma peritonei treated by cytoreductive surgery and intraperitoneal chemotherapy. World J Surg 2013;37(6):1263-70
   PubMed Web of Science ®Google Scholar
• Marcotte E, Dube P, Drolet P, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis. World J Surg Oncol 2014;12(1):332
   PubMedGoogle Scholar
• Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2007;14(2):484-92
   PubMed Web of Science ®Google Scholar
• Chua TC, Al-Alem I, Saxena A, et al. Surgical cytoreduction and survival in appendiceal cancer peritoneal carcinomatosis: an evaluation of 46 consecutive patients. Ann Surg Oncol 2011;18(6):1540-6
   PubMed Web of Science ®Google Scholar
• Sorensen O, Flatmark K, Reed W, et al. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei. Eur J Surg Oncol 2012;38(10):969-76
   PubMed Web of Science ®Google Scholar
• McBride K, McFadden D, Osler T. Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis. J Surg Res 2013;183(1):246-52
   PubMed Web of Science ®Google Scholar
• Smith JW, Kemeny N, Caldwell C, et al. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1992;70(2):396-401
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Zhu BW, Sese GB, Shmookler B. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993;36(4):323-9
   PubMed Web of Science ®Google Scholar
• Witkamp AJ, de Bree E, Kaag MM, et al. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001;88(3):458-63
   PubMed Web of Science ®Google Scholar